EveryONE Medicines shuts down, raising questions on FDA bespoke pathway scalability for ultra-small patient populations
SHERIDAN, WYOMING - March 04, 2026 - EveryONE Medicines has decided to close, shortly after the FDA released draft guidance intended to help drugmakers advancing personalized genetic medicines under a bespoke framework. Reporting cited an anonymous source who said the pathway was insufficient and difficult to work with for commercializing treatments aimed at exceedingly small patient populations, while a U.S. Department of Health and Human Services spokesperson rejected the idea that the FDA framework caused the shutdown. For rare-disease operators and investors, the development spotlights a core execution constraint in individualized medicines: whether regulatory expectations can be met repeatedly and economically when each therapy is effectively a one-off product.